EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cost‐effectiveness of risk‐stratified screening for cervical cancer in cohorts vaccinated against human papillomavirus with moderate vaccination coverage

Tiago M de Carvalho, Johannes Berkhof, Johannes A Bogaards iD

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70377 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Tiago M de Carvalho und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department Epidemiology and Data Science, Amsterdam UMC, Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Vaccines, Papillomavirus Infections, Early Detection of Cancer. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Horizon 2020 Framework Programme, EU4Health Programme (EU4H).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cervical cancer screening in the Netherlands consists of human papillomavirus (HPV) testing followed by cytological triage at age 30, 35, 40, 50, and 60 years. Women are also invited at age 45, 55 and 65 years if they did not test HPV‐negative 5 years earlier (risk‐based invitation). With influx of birth cohorts vaccinated against HPV, de‐intensification may be needed to maintain a cost‐effective program. We used an updated and recalibrated model of type‐specific HPV transmission and cervical carcinogenesis to estimate the cost‐effectiveness of 16 strategies with reduced screening intensity. Strategies varied by starting age, screening interval, and number of risk‐based invitations, possibly stratified for HPV vaccination status. Cost‐effectiveness was measured by net monetary benefit (NMB). A positive NMB indicates that a strategy is cost‐effective compared to the current policy. Two strategies without stratification for HPV vaccination status had a positive NMB. An NMB of EUR 1.6 million per 100,000 women was obtained when, compared to current screening, the invitation at age 35 was based on the HPV‐test result at age 30. An NMB of EUR 1.8 million per 100,000 women was obtained when women were re‐invited every 5 years if they were HPV‐positive or had not been tested 5 years earlier. If reduced screening was only applied to vaccinated women, the highest NMB was EUR 1.3 million per 100,000 women. Thus, reducing screening in HPV‐vaccinated cohorts is cost‐effective when re‐inviting women after 10 years if they test HPV‐negative. Stratification for HPV vaccination status does not improve the cost‐effectiveness of screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsPapillomavirus VaccinesPapillomavirus InfectionsEarly Detection of CancerHuman Papillomavirus VirusesVaccination CoverageHumansFemaleCost-Benefit AnalysisCost-Effectiveness AnalysisMiddle AgedNetherlandsAdultVaccinationMass ScreeningAged

Stichwörter der Autor:innen

HPV vaccinationHPV‐based screeningcervical cancercost‐effectiveness analysishuman papillomavirus

Substanzen

Papillomavirus Vaccines

Autor:innen und Institutionen

  • Department Epidemiology and Data Science, Amsterdam UMC, Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.
  • Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, The Netherlands.

ORCID-Profile: Johannes A Bogaards

Förderung

  • Horizon 2020 Framework Programme
  • EU4Health Programme (EU4H)

Zitieren

APA

de Carvalho, T. M., Berkhof, J., & Bogaards, J. A. (2026). Cost‐effectiveness of risk‐stratified screening for cervical cancer in cohorts vaccinated against human papillomavirus with moderate vaccination coverage. International Journal of Cancer. https://doi.org/10.1002/ijc.70377

Vancouver

de Carvalho TM, Berkhof J, Bogaards JA. Cost‐effectiveness of risk‐stratified screening for cervical cancer in cohorts vaccinated against human papillomavirus with moderate vaccination coverage. International Journal of Cancer. 2026. doi:10.1002/ijc.70377

BibTeX
@article{deCarvalho2026,
  author = {de Carvalho, Tiago M and Berkhof, Johannes and Bogaards, Johannes A},
  title = {Cost‐effectiveness of risk‐stratified screening for cervical cancer in cohorts vaccinated against human papillomavirus with moderate vaccination coverage},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70377}
}
Kostenlos starten →